Alogliptin – Cheap Research Essays

Assume that your group is a P&T committee of a health plan and you are a member on the committee. There is a new drug that would like to get onto your health plan’s formulary. Please conduct a systematic review including all the pharmacoeconomic literature on the drug and make a recommendation whether or not the drug should be included on your health plan’s formulary based on the results of the systematic review you conducted. No more than 10 pages double-spaced excluding figure 1 and table 1.

Submit a draft that has complete METHODS section, the number of studies included in your systematic review and Figure 1 on 4/12.
1.The article to create the paper is: “Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study”-UNDER “ALOGLIPTIN ARTICLE” PDF.
-WE HAVE TO USE A FEW ARTICLES BUT THAT ONE IS THE ONLY THAT HAS A PROTOCOL-
INSTRUCTIONS: METHODS:

Protocol and registration
5.) Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility criteria
6.) Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources
7.) Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search
8.) Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.

Data collection process
10.) Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.

READ ALSO :

13.) State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results
14.) Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2 ) for each meta-analysis.
Risk of bias across studies
15.) Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses
16.) Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.

A) PLEASE SEE THE TEMPLATE PDF FOR FIGURE 1 AND TABLE1 EXAMPLE AND INSTRUCTIONS.-UNDER “MANUSCRIPT TEMPLATE” PDF.

AND USE SAMPLE ARTICLE: “Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review” PDF FOR FIGURE 1 AND TABLE 1.
SEE BELLOW…

FIGURE 1. Sample Selection Flowchart (see Figure 1 in sample article “Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review”)

TABLE1. Summary of Studies Included in the Review (see Table 1 in sample article “Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review”)
MANUSCRIPT TEMPLATE:

ManuScript Template-THIS IS HOW IT LOOKS IN THE PDF.

METHODS
We conducted a systematic review using … (database such as PubMed, Medline, etc.). We used the key words … We included … (description of inclusion criteria) We excluded … (description of exclusion criteria)

B) Please follow Table 1 Checklist of Items to Include When Reporting a Systematic Review or Meta-Analysis in this article when writing your paper. -UNDER “PRISMA STATEMENT” PDF.

C)Guide to conducting a systematic review I:

UNDER-STEPS TO CONDUCT A SYSTEMIC REVIEW PDF.
D) Guide to conducting a systematic review II: